Order Article Reprints

Zurochka A, Dobrinina M, Zurochka V, Hu D, Solovyev A, Ryabova L, Kritsky I, Ibragimov R, Sarapultsev A. Seroprevalence of SARS-CoV-2 Antibodies in Symptomatic Individuals Is Higher than in Persons Who Are at Increased Risk Exposure: The Results of the Single-Center, Prospective, Cross-Sectional Study. Vaccines. 2021; 9(6):627. https://doi.org/10.3390/vaccines9060627

Zurochka, Alexandr, Maria Dobrinina, Vladimir Zurochka, Desheng Hu, Alexandr Solovyev, Liana Ryabova, Igor Kritsky, Roman Ibragimov, and Alexey Sarapultsev. 2021. "Seroprevalence of SARS-CoV-2 Antibodies in Symptomatic Individuals Is Higher than in Persons Who Are at Increased Risk Exposure: The Results of the Single-Center, Prospective, Cross-Sectional Study" Vaccines 9, no. 6: 627. https://doi.org/10.3390/vaccines9060627

Zurochka, A., Dobrinina, M., Zurochka, V., Hu, D., Solovyev, A., Ryabova, L., Kritsky, I., Ibragimov, R., & Sarapultsev, A. (2021). Seroprevalence of SARS-CoV-2 Antibodies in Symptomatic Individuals Is Higher than in Persons Who Are at Increased Risk Exposure: The Results of the Single-Center, Prospective, Cross-Sectional Study. Vaccines, 9(6), 627. https://doi.org/10.3390/vaccines9060627